NCT07480382Not yet recruiting
Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC
A Prospective, Single-Center, Single-Arm Trial to Validate the Safety and Efficacy of "Dual-Conversion" Therapy With Liver Venous Deprivation (LVD), Conventional Transarterial Chemoembolization (cTACE), Tislelizumab, and Lenvatinib for Initially Unresectable Hepatocellular Carcinoma in the Right Liver.
Source: ClinicalTrials.gov · Last updated 18 Mar 2026
Brief summary (registry, in English)
This study evaluates a novel "Dual-Conversion" strategy (mechanical volume conversion via LVD plus biological conversion via cTACE, Tislelizumab, and Lenvatinib) for patients with initially unresectable right-sided hepatocellular carcinoma (HCC). The primary goal is to assess the rate of successful conversion to R0 resection and the safety profile of this multi-modal approach.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 14 Mar 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 30 Dec 2027
- Lead sponsor
- Hong Wu
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07480382
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 1 Apr 2026 to the primary completion date, 30 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous systemic therapy for HCC.
- Contraindications to LVD, TACE, or the study drugs
Other illness
- Active autoimmune disease or history of organ transplantation.
Other
- Extrahepatic metastasis.
- Portal vein tumor thrombus involving the main trunk (Vp4).
Who the study is looking for
- Age 18-75 years.
- Confirmed HCC (histologically or by AASLD clinical criteria).
- Initially unresectable HCC limited to the right liver (due to insufficient FLR or tumor characteristics).
- Child-Pugh score ≤ 7 (Class A or early B).
- ECOG Performance Status of 0 or 1.
- Adequate organ function (marrow, hepatic, and renal).
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| West China Hospital，Sichuan University Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.